Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486165 | 0.85 | KMT2A (0.47) | TSHRALDH1A1TSPOSMN1; SMN2RAB9A | |
| SCHEMBL7475621 | 0.82 | TP53 (0.46) | TSHRALDH1A1KDM4EGLATP53 | |
| SCHEMBL31110123 | 0.80 | TSHR (0.41) | TSHRALDH1A1KDM4EGLATP53 | |
| SCHEMBL3930397 | 0.78 | TSPO (0.54) | TSHRALDH1A1KDM4EGLATSPO | |
| SCHEMBL3425912 | 0.78 | ALDH1A1 (0.36) | TSHRALDH1A1GLATSPOHTT | |
| SCHEMBL1497989 | 0.77 | TSHR (0.60) | TSHRALDH1A1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL4734285 | 0.76 | TSHR (0.56) | TSHRALDH1A1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL30490414 | 0.75 | TSHR (0.58) | TSHRALDH1A1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL27771692 | 0.75 | TSHR (0.58) | TSHRALDH1A1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL28171346 | 0.75 | TSHR (0.58) | TSHRALDH1A1KDM4ETP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453051-B2 | Cyclosporin derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-09-27 | — | — | US | disclosed |
| EP-2751127-B1 | CYCLOSPORIN DERIVATIVES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | LEAD DISCOVER CENTER GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2751127-A1 | CYCLOSPORIN DERIVATIVES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2014-07-09 | — | — | EP | disclosed |
| CN-103842372-A | Cyclosporin derivatives | MAX PLANCK GESELLSCHAFT | 2014-06-04 | — | — | CN | disclosed |
| WO-2013030208-A1 | CYCLOSPORIN DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-03-07 | — | — | WO | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0946519-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024771-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | CHP1, RYR2, CANX | TSHR 4800/4885ALDH1A1 4482/4885KDM4E 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.